BIOGEN INC. (BIIB)
Biological Products, (No Diagnostic Substances)
Latest Price
$217.36
TTM P/E
23.37
Normalized P/E
18.52
Div Yield
--
Book Value
126.71
P/B Ratio
1.72
Valuation metrics
adjust assumptions →EPS: $8.79
Book value / share: $124.37
Formula: √(22.5 × EPS × BVPS)
Graham Number
$156.83
28% downside
Norm. op. income: $4.6B (median of 3yr)
Tax rate: 16%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$237.25
+9% upside
Base FCF: $2.1B (median of recent 5yr)
Growth: -13%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$44.88
79% downside
EPS: $8.79
Target P/E: 19×
Formula: EPS × P/E
P/E Fair Value
$167.01
23% downside
Institutional Ownership
98.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| FMR LLC | 18.22M | $3.94B | 12.38% | +5.41M | 2026-06-30 |
| BlackRock, Inc. | 15.99M | $3.45B | 10.86% | +11.1K | 2026-06-30 |
| PRIMECAP MANAGEMENT CO/CA/ | 15.15M | $3.27B | 10.30% | +397.0K | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.65M | $2.08B | 6.56% | +113.7K | 2026-06-30 |
| STATE STREET CORP | 7.34M | $1.59B | 4.99% | +176.4K | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6.60M | $1.43B | 4.49% | +73.2K | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 4.45M | $957.0M | 3.02% | +106.7K | 2026-06-30 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.12M | $673.0M | 2.12% | +155.8K | 2026-06-30 |
| NORGES BANK | 2.58M | $557.0M | 1.75% | -58.8K | 2026-06-30 |
| MORGAN STANLEY | 2.41M | $520.0M | 1.64% | +240.3K | 2026-06-30 |